1XJD


Conserved Protein Domain Family
STKc_nPKC_theta

?
cd05619: STKc_nPKC_theta (this model, PSSM-Id:173709 is obsolete and has been replaced by 270770)
Click on image for an interactive view with Cn3D
Catalytic domain of the Protein Serine/Threonine Kinase, Novel Protein Kinase C theta
Serine/Threonine Kinases (STKs), Novel Protein Kinase C (nPKC), theta isoform, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The nPKC subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. PKCs are classified into three groups (classical, atypical, and novel) depending on their mode of activation and the structural characteristics of their regulatory domain. nPKCs are calcium-independent, but require DAG (1,2-diacylglycerol) and phosphatidylserine (PS) for activity. There are four nPKC isoforms, delta, epsilon, eta, and theta. PKC-theta is selectively expressed in T-cells and plays an important and non-redundant role in several aspects of T-cell biology. Although T-cells also express other PKC isoforms, PKC-theta is unique in that upon antigen stimulation, it is translocated to the plasma membrane at the immunological synapse, where it mediates signals essential for T-cell activation. It is essential for TCR-induced proliferation, cytokine production, T-cell survival, and the differentiation and effector function of T-helper (Th) cells, particularly Th2 and Th17. PKC-theta is being developed as a therapeutic target for Th2-mediated allergic inflammation and Th17-mediated autoimmune diseases.
Statistics
?
PSSM-Id: 173709
View PSSM: cd05619
Aligned: 3 rows
Threshold Bit Score: 680.539
Threshold Setting Gi: 56554577
Created: 31-Aug-2007
Updated: 17-Jan-2013
Structure
?
Program:
Drawing:
Aligned Rows:
  next features
Conserved site includes 31 residues -Click on image for an interactive view with Cn3D
Feature 1:active site [active site]
Evidence:
  • Comment:Based on the binding of peptide substrates and ATP analogs to the AGC kinases, PKA and PKB.

Sequence Alignment
?
Format: Row Display: Color Bits: Type Selection:
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1          #####   #            # #                                #               ## #  
1XJD_A        23 KMLGKGSFGKVFLAEFkktnQFFAIKALKKDvvlmdDDVECTMVEKRVLSLAweHPFLTHMFCTFQTkeNLFFVMEYLnG 102
gi 55962227  385 KMLGKGSFGKVFLAELkgsgQFFAVKALKKDvvlmdDDVECTMVERRVLSLAwdHPFLTHLYCTFQTkeNLFFVMEYLnG 464
gi 134024036 232 KMLGKGSFGKVFLAELkgtnQFFAIKVLKKDvvlmdDDVECTMVEKRVLSLAweHPFLTHLYCTFQTkeHLFFVMEYLnG 311
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1         # #                                    # # ## #         ##  #             #####
1XJD_A       103 GDLMYHIQSchkFDLSRATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDkdGHIKIADFGMCKENMLGDAKTNXFCGTP 182
gi 55962227  465 GDLMFHIQTchrFDLPRSTFYAAEIICGLQFLHSKGIVYRDLKLDNILLDtdGHIKIADFGMCKENIIGEARTCTFCGTP 544
gi 134024036 312 GDLMFHIQSchkFDLPRATFYAAEIVCGLQFLHSKGVVYRDLKLDNILLDmeGHIKIADFGMCKESMLGDAKTSTFCGTP 391
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1        #                          #     #  #                                           
1XJD_A       183 DYIAPEILLGqkyNHSVDWWSFGVLLYEMLIGQSPFHGQdeEELFHSIRMDNPFYPRWleKEAKDLLVKLFVrePEKRLG 262
gi 55962227  545 DYIAPEILLGqkyGTSVDWWSFGVLLYEMLIGQSPFHGHdeEELFQSIRTDDPCYPRWltRDARDILVKLFVrePERRLG 624
gi 134024036 392 DYIAPEILLGqkyNYSVDWWSFGVLLYEMLIGQSPFHGIdeEELFQSIRMDNPMYPRFlsMEAKDILIMLFVrePERRLG 471
                        250       260       270       280       290       300       310
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
Feature 1                                                                                    
1XJD_A       263 vrGDIRQHPLFREINWEELERKEIDPPFRPkvkspfDCSNFDKEFLNEKPRLSFadralinSMDQNMFRNFXFMNP 338
gi 55962227  625 vkGNIRQHPFFRETDWSALEERQVEPPFKPtvksanDCSNFDKEFINEKPRLSVtdrmminSMDQSMFENFSFINP 700
gi 134024036 472 vkGDIRQHCFFQHIDWGRLENREIEPPFKPkvksadDWSNFDKEFLNEKPRLSSsertlinSMDQNMFNNFSFVNP 547

| Disclaimer | Privacy statement | Accessibility |
NCBI Home NCBI Search NCBI SiteMap